Bausch + Lomb appoints new Chief Legal Officer and Ophthalmic Pharma President

Bausch & Lomb Corp

Christina Ackermann steps down as EVP & General Counsel and President, Ophthalmic Pharmaceuticals; departure effective April 28, 2023.
Bob Bailey appointed EVP & Chief Legal Officer, effective April 24, 2023.
Andrew Stewart appointed President, Ophthalmic Pharmaceuticals, effective April 24, 2023.
Bailey previously served as CLO at Datavant and Allergan; Stewart joins from AbbVie eye care.
Both Bailey and Stewart will join the executive management team.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christina M. Ackermann

Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals

BLCO · Bausch & Lomb Corp

Effective: 2023-04-28
Filed: April 12, 2023, 7:59 PM ET

On April 12, 2023, Bausch + Lomb Corporation (the “Company”) announced the upcoming departure of Christina M. Ackermann as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals of the Company.

Appointed

Andrew Stewart

President, Ophthalmic Pharmaceuticals

BLCO · Bausch & Lomb Corp

Effective: 2023-04-24
Filed: April 12, 2023, 7:59 PM ET

Andrew Stewart will be appointed as the Company’s President, Ophthalmic Pharmaceuticals

Appointed

A. Robert D. Bailey

Executive Vice President & Chief Legal Officer

BLCO · Bausch & Lomb Corp

Effective: 2023-04-24
Filed: April 12, 2023, 7:59 PM ET

A. Robert D. Bailey will be appointed as the Company’s Executive Vice President & Chief Legal Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christina M. Ackermann departed as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals at Bausch & Lomb Corp.

Action: departed
Role: Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals

Exact text from the filing

On April 12, 2023, Bausch + Lomb Corporation (the “Company”) announced the upcoming departure of Christina M. Ackermann as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Stewart was appointed as President, Ophthalmic Pharmaceuticals at Bausch & Lomb Corp.

Action: appointed
Role: President, Ophthalmic Pharmaceuticals

Exact text from the filing

Andrew Stewart will be appointed as the Company’s President, Ophthalmic Pharmaceuticals

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

A. Robert D. Bailey was appointed as Executive Vice President & Chief Legal Officer at Bausch & Lomb Corp.

Action: appointed
Role: Executive Vice President & Chief Legal Officer

Exact text from the filing

A. Robert D. Bailey will be appointed as the Company’s Executive Vice President & Chief Legal Officer

View on SEC.gov

Bausch & Lomb Corp filing history →

Source: SEC EDGAR

accession 0000950103-23-005621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.